LM Advisors’s Biogen BIIB Stock Holding History

LM Advisors’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-965	Closed	-$208K	–	190
2024 Q1	$208K	Hold	965	–	–	0.03%	206
2023 Q4	$250K	Buy	+965	New	+$237K	0.05%	177

Other funds holding BIIB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

LM Advisors's BIIB Position: Q2 2024 in Review

LM Advisors sold out of Biogen (BIIB) in Q2 2024, closing a stake of 965 shares — an estimated $208K sold.

LM Advisors first reported a position in BIIB in Q4 2023 and held it in 2 quarters. The position peaked at $250K in Q4 2023. 943 funds tracked by Wall St. Rank hold BIIB as of Q2 2024.

LM Advisors reported no remaining Biogen position as of Q2 2024 after selling out during the quarter.
LM Advisors sold 965 Biogen shares in Q2 2024, an estimated $208K.
LM Advisors first reported a position in Biogen in Q4 2023 and held it in 2 quarters.
LM Advisors's Biogen position peaked at $250K in Q4 2023.
943 funds tracked by Wall St. Rank held Biogen as of Q2 2024.

Based on LM Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.